[Featured Stock] Korea BNC Advances Development of 'Dream Obesity Drug' GLP-1 Agonist... 52-Week High

Korea BNC is showing strong performance. This is interpreted as being influenced by positive clinical news regarding glucagon-like peptide-1 (GLP-1), the so-called "dream obesity drug." As a favorable wind blows through the obesity treatment market and related stocks gain attention, Korea BNC is receiving the greatest benefit with the added news of its development of a GLP-1 agonist.

원본보기 아이콘

As of 9:25 AM on the 29th, Korea BNC is trading at 5,190 KRW, up 13.94% (635 KRW) compared to the previous day. It surpassed the 52-week high of 4,860 KRW recorded in September 2023. Korea BNC's stock price rose from the start of trading that day and reached a high of 5,330 KRW.

The previous day, U.S. biotech company Therapeutics reported positive results in a Phase 2 clinical trial for an obesity treatment, causing its stock price to surge over 120%. The results showed a 14.7% reduction in patient weight after 13 weeks of GLP-1 administration. This outcome was better than the obesity treatment clinical results from Eli Lilly and Novo Nordisk.

GLP-1 is an incretin hormone secreted in response to nutrients in the gastrointestinal tract. It is characterized by enhancing insulin secretion according to glucose concentration. While it has a strong insulin secretion stimulation effect, it has the advantage of not causing hypoglycemia, making it a new candidate drug for obesity and diabetes treatment.

Following the favorable news of obesity treatments from the U.S., Korea BNC announced that it will jointly develop a GLP-1 "agonist" for diabetes and obesity treatment with ProApTech. The two companies plan to utilize ProApTech's proprietary 'SelecAll' technology to jointly develop and commercialize sustained-release candidate substances for GLP-1 agonists and target proteins for diabetes and obesity treatment. They will apply ProApTech's click chemistry and artificial intelligence (AI)-based non-natural amino acid insertion technology along with site-specific albumin binding technology.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.